A Phase 1/1b, open-Label, multicentre, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with Atezolizumab in patients with selected incurable cancers
A Phase 1/1b, open-Label, multicentre, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with Atezolizumab in patients with selected incurable cancers
Press Ctrl +⌘ + to increase font size.
Press Ctrl -⌘ - to decrease font size.
Press Ctrl 0⌘ 0 to reset font size.